Citations

Showing 10 of 108083 citations.

Mother's Milk: In Sickness and In Health?
Kresin, Molly , Pullins, Christopher , Horn, Jennifer L. , Kresin, Molly M, Pullins, Christopher T

Mayo Clinic

Journal of Women's Health | November 15, 2017 | Volume: 26 | Issue: 11 | Pages: 1252-1254

10.1089/jwh.2017.6582 | PMID 28910181 Get It

Hemiarthroplasty and Total Hip Replacement for Displaced Intracapsular Fracture in Active Elderly Patients Did Not Differ for Function at 12 Years After Surgery
Abdel, Matthew P.

Mayo Clinic

Journal of Bone and Joint Surgery | November 15, 2017 | Volume: 99 | Issue: 22 | Pages: 1942-1942

10.2106/jbjs.17.00973 | PMID 29135668 Get It

Myocardial Cobalt Levels Are Elevated in the Setting of Total Hip Arthroplasty
Wright, Thomas C., Bois, Melanie C. , Amin, Md Shahrier , Fayyaz, Ahmed, Jenkins, Sarah M. , Wyles, Saranya P. , Day, Patrick L. , Murray, David , Trousdale, Robert T. , Anavekar, Nandan S., Edwards, William D. , Maleszewski, Joseph J. , Wyles, Cody C. , Wright, T. Carson, Day, Patrick

Mayo Clinic

Journal of Bone and Joint Surgery | November 15, 2017 | Volume: 99 | Issue: 22 | Pages: e118

10.2106/jbjs.17.00159 | PMID 29135673 Get It

Background: Arthroplasty implants commonly contain elemental metal that may undergo wear-related release. Recently, cases of hip implant-associated myocardial injury have been reported. However, we are not aware of any previous study that has systematically measured myocardial metal levels or examined the relationship with total hip arthroplasty (THA). Methods: Archives of our institution were queried for autopsies of individuals who had undergone THA between 1990 and 2013. Myocardial tissue samples were analyzed for cobalt (Co) and chromium (Cr) levels with inductively coupled plasma mass spectroscopy. Seventy-five Co/Cr-on-polyethylene THA cases were included (mean age at time of death = 77.4 years; 49% women) as were 73 non-arthroplasty controls matched for age, sex, and history of hypertension and diabetes mellitus. Results: Significantly higher median myocardial concentrations of Co were observed in individuals with THA compared with controls (0.12 versus 0.06 μg/g, p < 0.0001). The median Co concentration was 69% higher in patients who had undergone THA revision (0.169 μg/g) than in those who underwent primary THA (0.100 μg/g; p = 0.004). In general, higher Co levels were observed in those with multiple replaced joints, although this finding only trended toward significance. Cardiomegaly, interstitial fibrosis, and decreased ejection fraction were observed more frequently in the postmortem samples of patients with implants than in those of controls (p = 0.0002, 0.044, and 0.0039, respectively). Conclusions: We believe this to be the first study to quantify metal levels in cardiac tissue in patients with and without joint replacement. The elevated Co levels, in concert with cardiomegaly and increased interstitial fibrosis found during autopsy, in the arthroplasty cohort are novel, important findings. Although Co levels were significantly elevated above those in controls, the majority were below those seen in clinical case reports of death from Co cardiotoxicity associated with metal-on-metal prostheses. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder
Amare, Azmeraw T. , Schubert, Klaus Oliver , Clark, Scott R. , Papiol, Sergi , Heilbronner, Urs , Degenhardt, Franziska , Tekola‐Ayele, Fasil , Hsu, Yi‐Hsiang , Shekhtman, Tatyana , Adli, Mazda , Akula, Nirmala , Akiyama, Kazufumi , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Bhattacharjee, Abesh Kumar, Benabarre, Antonio , Bengesser, Susanne , Birner, Armin , Brichant‐Petitjean, Clara, Cervantes, Pablo , Chen, Hsi‐Chung , Chillotti, Caterina , Cichon, Sven , Cruceanu, Cristiana , Czerski, Piotr M. , Dalkner, Nina , Zompo, Maria Del , Étain, Bruno , Falkai, Peter , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Fullerton, Janice M. , Gard, Sébastien, Grigoroiu‐Serbânescu, Maria , Grof, Paul , Hashimoto, Ryota , Jamain, Stéphane , Jiménez, Esther , Kahn, Jean‐Pierre, Kassem, Layla, Kuo, Po‐Hsiu , Kato, Tadafumi , Kittel‐Schneider, Sarah , Kliwicki, Sebastian , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Leckband, Susan G. , Tortorella, Alfonso , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , Novák, Tomáš , O’Donovan, Claire , Ozaki, Norio , Ösby, Urban, Pfennig, Andrea , Potash, James B. , Reif, Andreas , Reininghaus, Eva Z. , Schalling, Martin , Schofield, Peter R. , Schweizer, Barbara , Severino, Giovanni , Shilling, Paul D. , Shimoda, Katzutaka, Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Stopková, Pavla , Maj, Mario , Turecki, Gustavo , Vieta, Eduard , Volkert, Julia, Zandi, Peter P. , Bauer, Michael , Alda, Martin , McMahon, Francis J. , Etain, B , Vieta, E , Schofield, Peter R , Cichon, Sven , Nöthen, Markus M , Alda, Martin , Fullerton, Janice M , Hou, Liping , Backlund, Lena , Bellivier, Frank , Biernacka, Joanna M. , Dalkner, Nina , Dayer, Alexandre G. , DePaulo, J Raymond , Garnham, Julie , Goes, Fernando , Hauser, Joanna , Herms, Stefan , Hoffmann, Per , Hofmann, Andrea , Kelsoe, John R , König, Barbara , Kusumi, Ichiro , McElroy, Susan L. , Colom, Francesc , Monteleone, Palmiero , Nievergelt, Caroline M , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Squassina, Alessio , Witt, Stephanie H. , Wright, A. Jordan , Mitchell, Philip B , Rietschel, Marcella , Schulze, Thomas , Baune, Bernhard , Amare, Azmeraw , Papiol, Sergi , Heilbronner, Urs , Chen, Hsi-Chung , Cruceanu, Cristiana , Czerski, Piotr , Jamain, Stéphane , Grigoroiu-Serbanescu, Maria , Kuo, Po-Hsiu , Kittel-Schneider, Sarah , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Novak, Tomas , Reif, Andreas , Stopkova, Pavla , Turecki, Gustavo , McMahon, Francis , Arias, Bárbara , Hashimoto, Ryota , Ozaki, Norio , Schubert, Klaus Oliver , Kato, Tadafumi , Mitjans, Marina , Manchia, Mirko

Mayo Clinic

JAMA Psychiatry | November 15, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamapsychiatry.2017.3433 | PMID 29121268 Get It

Syndromic Panel-Based Testing in Clinical Microbiology
Ramanan, Poornima , Bryson, Alexandra , Binnicker, Matthew J. , Pritt, Bobbi S. , Patel, Robin , Bryson, Alexandra L, Patel, Robin , Pritt, Bobbi S

Mayo Clinic

Clinical Microbiology Reviews | November 15, 2017 | Volume: 31 | Issue: 1 | Pages: No page available

10.1128/cmr.00024-17 | PMID 29142077 Get It

SUMMARY The recent development of commercial panel-based molecular diagnostics for the rapid detection of pathogens in positive blood culture bottles, respiratory specimens, stool, and cerebrospinal fluid has resulted in a paradigm shift in clinical microbiology and clinical practice. This review focuses on U.S. Food and Drug Administration (FDA)-approved/cleared multiplex molecular panels with more than five targets designed to assist in the diagnosis of bloodstream, respiratory tract, gastrointestinal, or central nervous system infections. While these panel-based assays have the clear advantages of a rapid turnaround time and the detection of a large number of microorganisms and promise to improve health care, they present certain challenges, including cost and the definition of ideal test utilization strategies (i.e., optimal ordering) and test interpretation.
Symptoms of Neurotoxicity among Carpenters Living in Rural Ecuador: A Population-based Study (The Atahualpa Project)
Brutto, Óscar H. Del , Mera, Robertino M. , Amador, Ani Reich de, Zambrano, Mauricio, Castillo, Pablo R. , Castillo, Pablo R

Mayo Clinic

Journal of Neurosciences in Rural Practice | November 15, 2017 | Volume: 08 | Issue: 04 | Pages: 649-652

10.4103/jnrp.jnrp_286_17 | PMID 29204030 Get It

ABSTRACT Background: There is no information on the prevalence of symptoms related to neurotoxicity among carpenters working in underserved populations. To assess the magnitude of the problem, we conducted a population-based study in Atahualpa, a rural Ecuadorian village, where most men work as carpenters under poor safety conditions. Methods: All men aged 40–75 years living in Atahualpa were identified during a door-to-door survey and evaluated with a general demographic questionnaire, the Q16 questionnaire, the depression axis of the Depression Anxiety Stress Scale-21, and the Montreal Cognitive Assessment (MoCA). Results: Among 230 participants, 63% were carpenters. Seventy participants (30%) had a positive Q16 questionnaire (≥6 points), which suggested neurotoxicity. In a logistic regression model adjusted for age, education, alcohol intake, symptoms of depression, and MoCA score, the proportion of Q16 positive persons was 39.1% for carpenters and 15.9% for noncarpenters (odds ratio: 3.53, 95% confidence interval: 1.75–7.15, P < 0.0001). In a generalized linear model, adjusted mean scores in the Q16 questionnaire were 4.9 for carpenters and 3.6 for noncarpenters (β: 1.285, standard error: 0.347, P < 0.0001). There was no correlation between scores in the Q16 questionnaire and the MoCA (Pearson correlation coefficient = −0.02), and the only significant covariate in the multivariate linear model was age, with every 10 years of age difference contributing 0.64 points in the Q16 questionnaire. Conclusion: This study shows a high prevalence of symptoms associated with neurotoxicity among carpenters after adjusting for a number of confounders. Long-term exposure to toxic solvents is the most likely explanation to this finding.
Contraceptive Options for the Perimenopausal Woman
Casey, Petra M., Marnach, Mary L. , Pruthi, Sandhya

Mayo Clinic

Clinical medicine. Reproductive health | November 15, 2017 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/cmrh.s886 Get It

CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease–Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis
Cox, Christian W. , Montner, Steven M. , Adegunsoye, Ayodeji , Husain, Aliya N. , Vij, Rekha, Noth, Imre , Lynch, David A. , Strek, Mary E. , Chung, Jonathan Hero , Oldham, Justin M

Mayo Clinic

American Journal of Roentgenology | November 15, 2017 | Volume: 210 | Issue: 2 | Pages: 307-313

10.2214/ajr.17.18384 | PMID 29140119 Get It

11 C-Choline PET/CT for Detection and Localization of Parathyroid Adenomas
Parvinian, Ahmad , Martin-Macintosh, Erica L., Goenka, Ajit H. , Durski, Jolanta M. , Mullan, Brian P., Kemp, Brad , Johnson, Geoffrey B. , Kemp, Brad J, Johnson, Geoffrey B

Mayo Clinic

American Journal of Roentgenology | November 15, 2017 | Volume: 210 | Issue: 2 | Pages: 418-422

10.2214/ajr.17.18312 | PMID 29140118 Get It

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
Altman, Jessica K. , Foran, James M. , Pratz, Keith W. , Trone, Denise, Cortes, Jörge E. , Tallman, Martin S. , Cortes, Jorge

Mayo Clinic

American Journal of Hematology | November 15, 2017 | Volume: 93 | Issue: 2 | Pages: 213-221

10.1002/ajh.24974 | PMID 29139135 Get It

AbstractNovel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline‐based induction/consolidation chemotherapy. Quizartinib is a selective and highly potent FLT3 inhibitor that has shown strong single‐agent activity in relapsed or refractory (R/R) AML. This phase 1, open‐label, sequential group dose‐escalation trial (NCT 01390337) is the first evaluating safety and tolerability of quizartinib in combination with SOC chemotherapy in newly diagnosed AML (ndAML). Nineteen patients unselected for FLT3 mutational status received one of three quizartinib dihydrochloride dose levels (DL): 60 mg/d for 7 days (DL1; n = 6), 60 mg/d for 14 days (DL2; n = 7), and 40 mg/d for 14 days (DL‐1; n = 6); administered orally starting on day 4 of chemotherapy. Median age was 43.8 years. Ten patients completed induction and consolidation. Three patients experienced dose‐limiting toxicities (DLTs): 2 at DL2 (1 pericardial effusion; 1 febrile neutropenia, decreased platelet count, and QT prolongation); 1 at DL‐1 (pericarditis). Maximum tolerated dose (MTD) was identified as DL‐1. Most common grade 3/4 adverse events were febrile neutropenia (47%), neutropenia (42%), thrombocytopenia (32%), and anemia (26%). There were no apparent additional toxicities with addition of quizartinib to chemotherapy although grade ≤1 QT prolongation was observed at MTD. Sixteen patients (84%) achieved a response; 14 (74%) composite complete response; 2 (11%) morphologic leukemia‐free state. The phase 3 QuANTUM‐First trial (NCT02668653) is further evaluating the effect of quizartinib plus SOC chemotherapy in ndAML FLT3‐ITD mutated patients.